Get the Daily Brief
Latest Biotech News
Tempus Expands AI Oncology Portfolio with Paige Acquisition
Tempus AI has acquired Paige, a digital pathology company, in an $81.25 million deal paid mostly in common stock, enhancing Tempus’ capabilities in cancer diagnosis and precision medicine. Paige...
Wugen Raises $115 Million for Off-the-Shelf CAR-T Cancer Therapy
Cell therapy startup Wugen has secured $115 million led by Fidelity to advance its allogeneic CAR-T therapy (WU-CART-007) targeting relapsed or refractory T-cell acute lymphoblastic leukemia and...
AbbVie Acquires Gilgamesh’s Psychedelic Depression Candidate for $1.2 Billion
AbbVie announced an agreement to acquire Gilgamesh Pharmaceuticals’ psychedelic drug candidate bretisilocin, a short-acting serotonin 5-HT2A receptor agonist in Phase II development for major...
BindCraft AI Enables One-Shot Functional Protein Design
Researchers at EPFL and MIT have introduced BindCraft, an AI-driven pipeline that designs functional protein binders in a single computational shot. Departing from traditional low-efficiency...
Advancements in Continuous Glucose Monitoring and Diabetes Care
A recent position paper from leading diabetes experts emphasizes the expanding role of continuous glucose monitoring (CGM) systems in managing Type 2 diabetes. CGMs facilitate real-time glucose...
AI and Imaging Innovations Pioneer Cancer Diagnostics and Treatment
Innovations in artificial intelligence and imaging are revolutionizing cancer care through improved diagnostics and personalized therapies. AI integration enables enhanced tumor profiling and...
New Discoveries in Ovarian Cancer Research and Biomarkers
Cutting-edge ovarian cancer studies have unveiled molecular targets and biomarkers critical for improving diagnosis and therapy. Research highlights include identification of laminin α5 and EDA...
Massachusetts Biotech Faces Funding and Investment Downturn
The Massachusetts biotech sector is experiencing a notable contraction, with venture capital investments dropping over 17% to $2.75 billion in the first half of 2025—the lowest since 2017....
Tempus Acquisition Broadens AI Pathology Capabilities
Tempus AI has expanded its precision medicine portfolio with the acquisition of Paige, a digital pathology firm holding nearly seven million digitized pathology slides from diverse populations...
Lilly’s Oral GLP-1 Orforglipron Advances Obesity Treatment
Eli Lilly released positive Phase III trial data for orforglipron, an oral GLP-1 receptor agonist targeting weight loss in individuals with obesity and type 2 diabetes. The study demonstrated...
AbbVie Acquires Gilgamesh’s Psychedelic Depression Drug
AbbVie has entered a $1.2 billion agreement to acquire Gilgamesh Pharmaceuticals’ lead psychedelic candidate, bretisilocin, for treating major depressive disorder. Bretisilocin is a novel...
Wugen Raises $115 Million to Advance Off-the-Shelf CAR-T Therapy
Wugen, a St. Louis-based biotech focused on developing off-the-shelf CAR-T therapies for T-cell malignancies, announced a $115 million financing round led by Fidelity Management & Research. The...
Massachusetts Biotech Faces Funding Slump Amid Federal Cuts
MassBio’s annual industry report exposes sharp declines in Massachusetts biotech funding. Venture capital investment fell over 17% in the first half of 2025 compared with 2024, reaching the lowest...
Regeneron’s Cemdisiran Achieves Phase III Success in Myasthenia Gravis
Regeneron Pharmaceuticals, licensing siRNA drug cemdisiran from Alnylam, announced positive Phase III trial outcomes in generalized myasthenia gravis. As a monotherapy, cemdisiran significantly...
Akeso’s PD-1/VEGF Bispecific Antibody Advances Lung Cancer Survival
Akeso Pharmaceuticals reported overall survival benefits in a China-only Phase III trial of its PD-1/VEGF bispecific antibody, ivonescimab, combined with chemotherapy for non-small-cell lung...
BindCraft AI Pipeline Excels in One-Shot Protein Binder Design
Researchers at EPFL unveiled BindCraft, an automated AI-driven pipeline achieving unprecedented 10-100% success rates designing functional protein binders in a single iteration. BindCraft targets...
Sarepta Reports Improved Safety for Duchenne Gene Therapy
Sarepta Therapeutics presented new safety data for its Duchenne Muscular Dystrophy gene therapy Elevidys, showing zero ambulatory patient deaths from acute liver failure among over 1,000 treated...
AbbVie Acquires Gilgamesh’s Psychedelic Candidate Bretisilocin for Depression
AbbVie has acquired Gilgamesh Pharmaceuticals’ lead investigational compound, bretisilocin (GM-2505), a short-acting serotonin 5-HT2A receptor agonist designed to treat moderate-to-severe major...
Lilly Advances Oral GLP-1 Orforglipron for Obesity and Diabetes
Eli Lilly announced positive phase III results for orforglipron, an oral GLP-1 receptor agonist aimed at adults with obesity or overweight with type 2 diabetes. The oral therapy demonstrated...
Regeneron’s Cemdisiran Meets Phase III Endpoints in Myasthenia Gravis
Regeneron's small interfering RNA drug cemdisiran, licensed from Alnylam Pharmaceuticals, met primary and secondary endpoints in a pivotal phase III trial for generalized myasthenia gravis....